Key result
The monoclonal antibody B8E5 inhibits beta-adrenergic-stimulated L-type Ca2+ currents through activation of the M2 muscarinic receptor by increasing cGMP.
The monoclonal antibody B8E5 inhibits beta-adrenergic-stimulated L-type Ca2+ currents via M2 muscarinic receptor activation, acting through a cGMP-dependent pathway.
Hypothesis-generating in animal models; leaves open any role for B8E5-like antibodies in human cardiac disease.
The effects of a monoclonal antibody (B8E5) directed against the second extracellular loop of the muscarinic M(2) receptor were studied on the L-type Ca(2+) currents (I(Ca,L)) of guinea pig ventricular myocytes using the whole cell patch-clamp technique. Similar to carbachol, B8E5 reduced the isoproterenol (ISO)-stimulated I(Ca,L) but did not significantly affect basal I(Ca,L). Atropine blocked the inhibitory effect of B8E5. The electrophysiological parameters of ISO-stimulated I(Ca,L) were not modified in presence of B8E5. Inhibition of I(Ca,L) by B8E5 was still observed when intracellular cAMP was either enhanced by forskolin or maintained constant by using a hydrolysis-resistant cAMP analog (8-bromoadenosine 3',5'-cyclic monophosphate) or by applying the phosphodiesterase inhibitor IBMX. The effect of B8E5 was mimicked by 8-bromoguanosine 3',5'-cyclic monophosphate, a potent stimulator of cGMP-dependent protein kinase, and prevented by a selective inhibitor of nitric oxide-sensitive guanylyl cyclase [1H-(1,2,4)oxadiazolo[4,3-a]quinoxaline-1-one]. These results indicate that the antibody B8E5 inhibits the beta-adrenergic-stimulated I(Ca,L) through activation of the M(2) muscarinic receptor and further suggest that the antibody acts not via the classical pathway of decreasing intracellular cAMP, but rather by increasing cGMP.
No takes yet. Share an insight, caveat, or question.
Nascimento et al. (2001) studied this question. Monoclonal antibody B8E5 was evaluated on L-type Ca(2+) currents (I(Ca,L)). The monoclonal antibody B8E5 inhibits beta-adrenergic-stimulated L-type Ca2+ currents through activation of the M2 muscarinic receptor by increasing cGMP.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: